ABSTRACT
The prognostic value of the circulating tumor cells (CTCs), defined as EpCAM+, Cytokeratin (8, 18, 19)+ and CD45-nucleated cells, has been provided in metastatic breast cancer (mBC), with Level I of evidence. However, CTCs belong to a heterogeneous pool of rare cells, and there isn’t consensus on an univocal definition of CTCs. Here, we present a definition of metabolically altered CTCs (MBA-CTC) as CD45-negative cells with an increased extracellular acidification rate (iECAR), supported by the presence of iECAR among the hallmarks of cancer. We tested the prognostic value of MBA-CTC present in mBC patients before starting a new systemic therapy (T0) and 3-4 weeks after (T1). Samples were analyzed in parallel with CellSearch platform (CS). Standard RECIST criteria were used to determine patients’ responses to treatment.
In our cohort of n=31 mBC patients, a level of MBA-CTCs above the cut-off was associated with: i) a shorter median PFS both pre-therapy (123 days vs 306; p<0.0001) and during therapy (139 vs 266 days; p= 0.0009); ii) a worse OS both pre-therapy (p=0.0003, 82% survival vs 20%) and during therapy (p=0.0301, 67% survival vs 38%); iii) good agreement with therapy response (kappa=0.685). Both the trend of MBA-CTCs over time and the combined results of the two assays (MBA and CS) enabled more accurate stratification. MBA and CS results showed fair (K=0.33) and poor (K=0.077) agreement at T0 and T1, respectively. This fact and the increased accuracy in combining results suggest that the assays detect different CTC subsets. In conclusion, MBA-CTCs does provide prognostic information at least equivalent to CS, and are even more informative when analyzed over time or combined with CS-CTCs.
Competing Interest Statement
F.D.B., M.T., A.P., and W.T.S.H., are co-authors of the patent Pub. No.: WO/2015/092726 METHOD FOR DETECTING CIRCULATING TUMOUR CELLS (CTCS) and co-founders of a related start-up company. All other authors declare that they have no competing interests.
Clinical Trial
This observational prospective study was approved by the internal review board of Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. The study did not require additional collection of samples from patients, since leftovers from routine lab analysis were used.
Funding Statement
This work was supported by CRO Aviano Intramural Research Grants-2014, ERC Monalisa QuidProQuo grant (Advanced Grant No. 269051), ERC “A Cactus” (poc Grant No.640955) proof of concept grant and AIRC IG “Dissecting the heterogeneity of circulating tumor cells in metastatic breast cancer: association with metastatic pattern and clinical outcome”. CUP: G23C17000800007 (ID 20443). The TITAN X used for this research was donated by the NVIDIA Corporation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors jointly supervised this work.
Data Availability
All data are available in the text and supplementary materials.
